MOSCOW, February 20. /TASS/. The EpiVacCorona COVID-19 vaccine will be able to protect a person for one year, Director General of the Vector State Research Center of Virology and Biotechnology Rinat Maksyutov said on Saturday.
"We expect that the immunity that is provided after immunization with the EpiVacCorona vaccine will last 12 months," he told the Rossiya 24 TV channel.
Maksyutov stressed that the efficacy of EpiVacCorona against the UK strain of COVID-19 has already been proven. The theoretical analysis also suggests that the vaccine will protect against South African and Brazilian mutations, he noted.
On July 24, 2020, the Vector research center received the Russian Health Ministry’s permit to conduct clinical trials of its vaccine on volunteers. They were completed on September 30. On October 14, Russian President Vladimir Putin said that the vaccine developed by Vector had received a registration certificate. On November 16, the Health Ministry issued a permit for post-registration trials of the vaccine on 150 volunteers over the age of 60, and a permit for trials on 3,000 volunteers over 18 years old was issued on November 18.